Jacob Bell

Frederick, Washington, D.C.

Dad says I'm not an effective communicator. Senior Reporter @biopharmadive. Formerly @TheStreet, @educationweek, @mcclatchydc.

Articles

Lilly to buy pain drug developer SiteOne, challenging Vertex

1 week ago | pharmavoice.com | Jacob Bell |Jacob Bell

This audio is auto-generated. Please let us know if you have feedback. Eli Lilly is wagering up to $1 billion on a private biotechnology company developing new, non-opioid pain drugs that have already caught the attention of other large pharmaceutical firms. Per an announcement Tuesday, Lilly plans to acquire SiteOne Therapeutics in an all-cash deal. The companies aren’t disclosing how much money is being exchanged upfront or when they expect the transaction to close.
Lilly to buy pain drug developer SiteOne, challenging Vertex

1 week ago | biopharmadive.com | Jacob Bell

Eli Lilly is wagering up to $1 billion on a private biotechnology company developing new, non-opioid pain drugs that have already caught the attention of other large pharmaceutical firms. Per an announcement Tuesday, Lilly plans to acquire SiteOne Therapeutics in an all-cash deal. The companies aren’t disclosing how much money is being exchanged upfront or when they expect the transaction to close.
Sanofi gains experimental Alzheimer’s drug through Vigil buyout

2 weeks ago | biopharmadive.com | Jacob Bell

Sanofi has agreed to spend $470 million to take control of a young biotechnology company and its experimental drug for Alzheimer’s disease. The newly announced acquisition has Sanofi paying $8 for each share of Vigil Neuroscience it doesn’t already own, reflecting a premium of nearly 250% to the price Vigil shares traded at Wednesday afternoon.
BioMarin to buy rare disease drugmaker Inozyme for $270M

3 weeks ago | biopharmadive.com | Jacob Bell

BioMarin Pharmaceutical has agreed to spend $270 million to take control of a Boston-based drug company with complementary expertise in rare disease research. The all-cash deal, announced Friday, should close sometime between July and the end of September, having already received unanimous backing from the boards of both BioMarin and its target Inozyme Pharma.
FDA delays approval decision for Biohaven rare disease drug

3 weeks ago | biopharmadive.com | Jacob Bell

Connecticut-based Biohaven has been developing what it hopes will be the first medicine for a group of rare, nerve-destroying diseases. The company ran a couple late-stage clinical trials, submitted an approval application to the Food and Drug Administration, and expected a verdict sometime before the end of September.
Galapagos backtracks on planned split

3 weeks ago | finance.yahoo.com | Jacob Bell

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. The Belgium-based drugmaker Galapagos is considering reversing course on plans to split into two biotechnology companies.
Galapagos backtracks on planned split

3 weeks ago | biopharmadive.com | Jacob Bell

The Belgium-based drugmaker Galapagos is considering reversing course on plans to split into two biotechnology companies. In an announcement Tuesday, Galapagos said its board of directors decided to re-evaluate the separation because of “regulatory and market developments.” The company is now exploring “all strategic alternatives for its existing businesses” and, moving forward, the focus will be to direct as many resources as possible at “transformative” business development deals.
Viatris’ new form of old pain drug scores in large trials

1 month ago | biopharmadive.com | Jacob Bell

Pittsburgh-based pharmaceutical firm Viatris on Thursday said a pain drug it’s been developing succeeded in two large clinical trials, setting the stage for an approval filing later this year. The drug is a reformulated version of an old medication, meloxicam, designed to more quickly treat the sharp, “acute” pain felt after an injury or operation. Researchers evaluated the drug in a dental pain study in 2022.
Facing ‘uncertainty on steroids,’ biotech dealmakers tread more cautiously

1 month ago | finance.yahoo.com | Jacob Bell

This story was originally published on BioPharma Dive. To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Coming into the year, deal experts were optimistic that, after months without a flashy buyout, the pharmaceutical industry was ready to do more and larger transactions. Legal and financial teams were pulled into many “substantive meetings” for “real deals to get done,” according to Andrew Merken, shareholder at the law firm Polsinelli.
Facing ‘uncertainty on steroids,’ biotech dealmakers tread more cautiously

1 month ago | biopharmadive.com | Jacob Bell

Coming into the year, deal experts were optimistic that, after months without a flashy buyout, the pharmaceutical industry was ready to do more and larger transactions. Legal and financial teams were pulled into many “substantive meetings” for “real deals to get done,” according to Andrew Merken, shareholder at the law firm Polsinelli. And their hopes were seemingly affirmed when, in mid-January, Johnson & Johnson agreed to purchase a brain drug developer for nearly $15 billion.